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Nilsson L, Madsen K, Topcu SO, Jensen BL, Frøkiær J, Nørre-
gaard R. Disruption of cyclooxygenase-2 prevents downregulation of
cortical AQP2 and AQP3 in response to bilateral ureteral obstruction in
the mouse. Am J Physiol Renal Physiol 302: F1430–F1439, 2012. First
published March 7, 2012; doi:10.1152/ajprenal.00682.2011.—Bilateral
ureteral obstruction (BUO) in rats is associated with increased cyclo-
oxygenase type 2 (COX-2) expression, and selective COX-2 inhibi-
tion prevents downregulation of aquaporins (AQPs) in response to
BUO. It was hypothesized that a murine model would display similar
changes in renal COX-2 and AQPs upon BUO and that targeted
disruption of COX-2 protects against BUO-induced suppression of
collecting duct AQPs. COX-2/ and wild-type littermates
(C57BL/6) were employed to determine COX-1, -2, AQP2, and AQP3
protein abundances and localization after BUO. In a separate series,
sham and BUO wild-type mice were treated with a selective COX-2
inhibitor, parecoxib. The COX-2 protein level increased in wild-type
mice in response to BUO and was not detectable in COX-2/.
COX-1 protein abundance was increased in sham-operated and BUO
mice. Total AQP2 and -3 mRNA and protein levels decreased signif-
icantly after BUO in the cortexouter medulla (COM) and inner
medulla (IM). The decrease in COM AQP2 and -3 levels was
attenuated/prevented in COX-2/ mice, whereas there was no
change in the IM. In parallel, inhibition of COX-2 by parecoxib
rescued COM AQP3 and IM AQP2 protein level in wild-type mice
subjected to BUO. In summary, 1) In C57BL/6 mice, ureteral obstruc-
tion increases renal COX-2 expression in interstitial cells and lowers
AQP2/-3 abundance and 2) inhibition of COX-2 activity by targeted
disruption or pharmacological blockade attenuates obstruction-
induced AQP downregulation. In conclusion, COX-2-derived prosta-
glandins contribute to downregulation of transcellular water transport-
ers in the collecting duct and likely to postobstruction diureses in the
mouse.
COX-2; parecoxib
PREVIOUS STUDIES INDICATE that the cyclooxygenase (COX)-PG
pathway may contribute to renal functional changes after
ureteral obstruction (1, 16, 28). Two isoforms of COX have
been identified, namely, COX-1 and COX-2. It has been
demonstrated that 24-h bilateral ureteral obstruction (BUO)
enhances PGE2 production in cortical and medullary tubules of
the rat kidney (28), and we have recently demonstrated that
COX-2 is the predominant isoform that is responsible for
accumulation of PGE2, PGF2, prostacyclin metabolite 6-keto-
PGF1, and thromboxane-2 in rat kidney tissue in response to
BUO (18).
It is well established that BUO and release of BUO is
associated with a marked decrease in renal aquaporin (AQP)
levels and collecting duct water permeability (6, 12, 16).
Previously, it was demonstrated that selective COX-2 inhibi-
tion prevents downregulation of AQP2 in response to BUO in
the inner medulla (IM) (16–18) and restores urine output
toward normal in the first hours after release of obstruction in
rats (1). The major effect of prostaglandins on water transport
appears to be mediated by the binding of PGE2 to the EP3
receptor, subsequently inhibiting increased intracellular
cAMP, thereby hindering vasopressin-mediated delivery of
AQP2 to the plasma membrane in cortical collecting duct
principal cells (7, 25). However, a recent study showed that
prolonged treatment with a selective EP4 receptor agonist of a
mice model in which the V2 vasopressin receptor (V2R) gene
is conditionally deleted prevents downregulation of renal
AQP2 levels, probably due to EP4 receptor-mediated elevation
of cAMP levels in kidney collecting duct cells (14). Moreover,
Olesen et al. (21) demonstrated that EP2 and EP4 agonists
increase both AQP2 phosphorylation and trafficking. We have
demonstrated that COX-2 knockout mice (COX-2/) exhibit
lower urine concentrating ability despite increased AQP2 and
AQP3 abundances (19). Taken together, these contradictory
observations on the regulatory impact of prostaglandins on
renal aquaporin abundance/water transport prompt investiga-
tions into model systems where the contribution from distinct
components of the very redundant system can be defined more
precisely. Thus, to gain insight into the role of COX-2 in the
obstruction-induced renal AQP changes and overcome the
inherent challenges associated with drug specificity in pharma-
cological approaches, we decided to transfer from a rat to a
murine model system and employ mice with targeted disrup-
tion of COX-2. We hypothesized that complete ureteral ob-
struction in the mouse leads to increased renal COX-2 expres-
sion and COX-2-dependent downregulation of collecting duct
AQP2 and AQP3. To address this question, COX-2/ and
wild-type littermate mice on a C57BL/6 background were used
for the experiments. The mild developmental renal injury in
COX-2/ on a C57BL/6 background (19, 29) with higher
levels of AQP2 and AQP3 was not considered a drawback to
test the present hypothesis regarding downregulation of AQPs
in response to BUO. Wild-type and COX-2/ mice were
subjected to BUO for 24 h, and renal tissue abundance and
localization of COX-2, COX-1, and collecting duct AQP2 and
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-3 were determined. To ensure that observations were caused
by abolished COX-2 activity, experiments were repeated in
wild-type mice that were treated with the selective COX-2
inhibitor parecoxib during 24-h BUO.
MATERIALS AND METHODS
COX-2/ Mice
COX-2/ mice on a mixed 129/C57 background were origi-
nally generated by Dinchuk et al. (3). The breeder pairs were
obtained from The Jackson Laboratory (Bar Harbor, ME) on a
predominant C57BL/6J background. Animals were further back-
crossed to the C57BL/6J genetic background for two consecutive
generations before they were used for experiments. Mice were
housed at The Biomedical Laboratory, University of Southern
Denmark and genotyped as previously described (5). All proce-
dures conformed to the Danish National Guidelines for the care
and handling of animals and the published guidelines from the
National Institutes of Health. The animal protocols were approved
by the board of the Institute of Clinical Medicine, Aarhus Univer-
sity, according to the licenses for use of experimental animals
issued by the Danish Ministry of Justice.
Experimental Animals
Studies were performed in COX-2/ and wild-type mice. The
animals had free access to a standard rodent diet (Altromin, Lage,
Germany) and tap water. During the experiments, animals were
kept in individual cages, with a 12:12-h light-dark cycle, a tem-
perature of 21  2°C, and a humidity of 55  2%. Animals were
allowed to acclimatize to the cages 3– 4 days before surgery. The
animals were placed on anesthesia with isoflurane (Abbott Scan-
dinavia), and during the operation the animals were placed on a
heating pad to maintain rectal temperature at 37–38°C. Through a
midline abdominal incision, both ureters were exposed and then
occluded with a silk ligature.
Animals were allocated to the protocols indicated below. Age-
and time-matched, sham-operated controls were prepared and were
observed in parallel with each BUO group in the following proto-
cols.
Protocol 1. BUO was induced for 24 h in COX-2/ and wild-type
mice (n  10). The kidneys were prepared for semiquantitative
immunoblotting and quantitative PCR (QPCR; n  6) or for immu-
nohistochemistry (n  4). Sham-operated controls were prepared in
parallel (n  9), and the kidneys were prepared for semiquantita-
tive immunoblotting and QPCR (n  6) or for immunohistochem-
istry (n  3).
Protocol 2. Prior to surgery, wild-type mice were injected with a
selective COX-2 inhibitor, parecoxib (Pfizer), dissolved in saline (5
mg·kg1·day1) for 7 days. Injections with saline as a control were
conducted in parallel. BUO was induced for 24 h in mice in both
parecoxib-treated (n  5) and saline-treated (n  6) mice. Sham-
operated controls were prepared in parallel in both parecoxib-treated
(n  4) and saline treated (n  6) mice. The kidneys were prepared
for semiquantitative immunoblotting.
Administration of a dose at 5 mg·kg1·day1 parecoxib was
chosen according to a pharmacological profile study of pareco-
xib (23).
Blood Sampling and Removal of Kidneys
Twenty-four hours after induction of BUO, mice were reanes-
thetized with isoflurane. Before death, the aortic bifurcation of the
mouse was localized, dissected free, and a blood sample was
collected for the determination of plasma electrolytes and osmo-
lality. Rapidly, the kidneys were removed and dissected into the
cortex and IM. The plasma concentrations of sodium, potassium,
creatinine, and urea were measured (Vitros 950,
Johnson&Johnson). Finally, the osmolality of the plasma was
determined with a vapor pressure osmometer (Osmomat 030,
Gonotec, Berlin, Germany).
Isolation of RNA and QPCR
Total RNA was isolated from mouse cortex and IM with a
NucleoSpin RNA II mini kit according to the manufacturer’s
instructions (Macherey-Nagel). RNA was quantitated by spectro-
photometry and stored at 80°C. cDNA synthesis was performed
on 0.5 g RNA with an AffinityScript QPCR cDNA synthesis kit
(Stratagene).
For QPCR, 100 ng cDNA served as a template for PCR ampli-
fication using Brilliant SYBR Green QPCR Master Mix according
to the manufacturer’s instructions (Stratagene). Serial dilution (1
ng–1 fg/l) of cDNA was used as a template for generation of a
standard curve. Nested primers were used to amplify standards and
kidney cDNA samples: COX-2: sense 5=- GCA GCC AGT TGT
CAA ACT GC-3=; antisense 5=-CTC GGA AGA GCA TCG CAG
AGG-3=; GenBank accession no. NM_011198.2; AQP2: sense
5=-CTT CCT TCG AGC TGC CTT C-3=; antisense 5=-CAT TGT
TGT GGA GAG CAT TGA C-3=; GenBank accession no.
NM_009699.2; AQP3: sense 5=-TGT GTG TAC TGG CCA TCG
TT-3=; antisense 5=-GTT GAC GGC ATA GCC AGA AT-3=;
GenBank accession no. AF104416.1; AQP4: sense 5=-GCA TCG
CTA AGT CCG TCT TC-3=; antisense 5=-GGG AGG TGT GAC
CAG GTA GA-3=; GenBank accession no. U88623; and GAPDH:
sense 5=-TAA AGG GCA TCC TGG GCT ACA CT-3=; antisense
5=-TTA CTC CTT GGA GGC CAT GTA GG-3=; GenBank acces-
sion no. M32599.1. Standards and unknown samples were ampli-
fied in duplicate in 96-well plates, and PCR was performed for 40
cycles consisting of denaturation for 30 s at 95°C followed by
annealing and polymerization at 60°C for 1 min. Emitted fluores-
cence was detected during the annealing/extension step in each
cycle. A post-run melting-curve analysis was performed to ensure
Table 1. Body and kidney weight and plasma biochemical values from sham-operated and BUO wild-type
and COX-2/ mice
Sham BUO
Wild-type COX-2/ Wild-type COX-2/
Body weight, g 21.6  2.4 21.0 1.5 24.2 1.1 21.8 1.2
Kidney weight, mg/g body wt 6.59 0.20 4.99 0.01† 7.94 0.00* 7.03 0.45*
Plasma creatinine, mol/l 7.3  1.1 14.7  2.4† 234.5 11.4* 266.8 16.3*
Plasma urea, mmol/l 4.9 0.3 24.6  6.5† 68.6 1.8* 86.9 11.0*
Plasma osmolality, mosmol/kgH2O 317.2  2.9 348.0 12.7† 412.8 13.0* 437.4 17.4*
Plasma potassium, mmol/l 4.5 0.2 5.1  0.4 8.6  0.3* 9.7 0.3*‡
Plasma sodium, mmol/l 142.8 0.9 144.2 2.4 142.1 0.9 140.6 1.0
Values are means SE. BUO, bilateral ureteral obstruction; COX, cyclooxygenase. *P 0.05 BUO-operated compared with sham-operated mice. †P 0.05
sham-operated wild-type compared with sham-operated COX-2/ mice, ‡P  0.05 BUO-operated wild-type compared with BUO-operated COX-2/ mice.
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only one amplification product. Selected samples were subjected to
gel electrophoresis to confirm the expected size of the product and
only one product.
Membrane Fractionation for Immunoblotting
The tissue [cortexouter medulla (COM) and IM] was ho-
mogenized in dissecting buffer (0.3 M sucrose, 25 mM imidazole,
1 mM EDTA, pH 7.2) containing the following protease inhibitors:
8.5 M leupeptin (serine and cysteine protease inhibitor, Sigma-
Aldrich, St. Louis, MO) and 0.4 mM Pefabloc (serine protease
inhibitor, Roche). The tissue was homogenized (30 s at 1,250 rpm)
by an Ultra-Turrax T8 homogenizer (IKA Labortechnik) and then
centrifuged at 4,500 g at 4°C for 15 min. Gel samples were
prepared from the supernatant in Laemmli sample buffer contain-
Fig. 1. A: cyclooxygenase (COX)-2 mRNA level in cortical and outer medullary (COM) kidney tissue. B: semiquantitative immunoblots of COX-2 (Cayman 160126)
expression in protein isolated from COM kidney tissue. C: semiquantitative immunoblots of COX-2 (Cayman 160126) expression in protein isolated from inner
medullary (IM) kidney tissue. D: anti-COX-2 antibody was preincubated with an excess of the immunizing peptide. Semiquantitative immunoblots of COX-2 expression
in protein isolated from IM kidney tissue in bilateral ureteral obstruction (BUO)-operated COX-2/ and wild-type mice probed with an additional 2 COX-2 antibodies:
Cayman 160106 and Abcam ab15191. E: immunohistochemical staining of COX-2 in IM tissue from BUO-operated wild-type mouse. COX-2 is localized in IM
interstitial cells. F: immunohistochemical staining of COX-2 in IM tissue from BUO COX-2/ mice showing no labeling of COX-2.
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ing 2% SDS. The total protein concentration of the homogenate
was measured using a Pierce BCA protein assay kit (Roche).
Electrophoresis and Immunoblotting
Samples of membrane fractionation from the different zones were run
on 12% polyacrylamide minigels (Bio-Rad Mini Protean II). For each
gel, an identical gel was run in parallel and subjected to Coomassie
staining. The Coomassie-stained gel was applied to determine identical
loading or to allow for correction for minor variations in loading.
Samples were run on 12% polyacrylamide gels (Bio-Rad Protean
II). Proteins were transferred to a nitrocellulose membrane (Hybond
ECL RPN 3032D, Amersham Pharmacia Biotech). Afterward, the
blots were blocked with 5% nonfat dry milk in PBS-T (80 mM
Na2HPO4, 20 mM NaH2PO4, 100 mM NaCl, 0.1 Tween 20, adjusted
to pH 7.4). After washing in PBS-T, the blots were incubated with
primary antibodies overnight at 4°C. The antigen-antibody complex
was visualized with horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (P448, diluted 1:3,000, Dako, Glostrup, Denmark)
using the enhanced chemiluminescence system (ECL; Amersham
Pharmacia Biotech). Immunolabeling controls were performed using
peptide-absorbed antibody.
Primary Antibodies
For semiquantitative immunoblotting and immunohistochemistry,
we used specific antibodies to renal COX-2 (160126 and 160106,
Cayman Chemical, Ann Arbor, MI); COX-2 (ab15191, Abcam, Cam-
Fig. 2. Effect of BUO on renal regulation of COX-1 protein abundance in
COX-2/ and wild-type mice. A: COM COX-1 abundance is significantly
increased in sham-operated COX-2/ mice compared with wild-type mice.
COX-1 is significantly increased in response to BUO in both wild-type and
COX-2/ mice. B: IM COX-1 abundance is significantly increased in sham-
operated COX-2/ compared with sham-operated wild-type mice. IM COX-1
protein abundance is significantly increased in wild-type mice in response to
BUO. *P  0.05 BUO-operated compared with sham operated mice. #P  0.05
sham-operated wild-type compared with sham-operated COX-2/ mice. ¤P 
0.05 BUO-operated wild-type compared with BUO-operated COX-2/ mice.
Fig. 3. Effect of BUO on COM regulation of aquaporin-2 (AQP2) in
COX-2/ and wild-type mice. A: in wild-type mice, COM AQP2 mRNA
level is significantly decreased as an effect of BUO, but the downregulation is
attenuated in COX-2/ BUO mice. B: COM AQP2 protein abundance is
significantly downregulated in wild-type BUO mice, but the downregulation
is absent in COX-2/ BUO mice. *P  0.05 BUO-operated compared with
sham-operated mice. ¤P  0.05 BUO-operated wild-type compared with
BUO-operated COX-2/ mice. C–F: cortical immunohistochemical staining
of AQP2 showed stronger labeling in COX-2/ BUO mice compared with
wild-type BUO mice. C: sham wild-type. D: sham COX-2/. E: BUO
wild-type. F: BUO COX-2/.
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bridge, UK); COX-1 (160109, Cayman Chemical); and AQPs, which
had been well characterized in previous studies: AQP-2 (H7661) (15),
pAQP2Ser256 (KO407) (2), AQP-3 (LL178AP) (4).
Immunohistochemistry
The kidneys from BUO and sham-operated control mice were fixed
by retrograde perfusion via the abdominal aorta with 3% paraformal-
dehyde in 0.1 M cacodylate buffer, pH 7.4. Moreover the kidneys
were immersion fixed for 1 h and washed for 3  10 min with 0.1 M
cacodylate buffer. The kidney blocks were dehydrated and embedded
in paraffin. The paraffin-embedded tissues were cut in 2-m sections
on a rotary microtome (Leica Microsystems, Herlev, Denmark).
For immunoperoxidase labeling, the sections were deparaffinated
and rehydrated. Endogenous peroxidase activity was blocked with 5%
H2O2 in absolute methanol for 10 min at room temperature. To expose
antigens, kidney sections were boiled in a target retrieval solution (1
mmol/l Tris, pH 9.0, with 0.5 mM EGTA) for 10 min. After cooling,
nonspecific binding was prevented by incubating the sections in 50
mM NH4Cl in PBS for 30 min, followed by blocking in PBS
containing 1% BSA, 0.05% saponin, and 0.2% gelatin. Sections were
incubated with primary antibodies diluted in PBS with 0.1% BSA and
0.3% Triton X-100 overnight at 4°C. After being washed 3  10 min
with PBS supplemented with 0.1% BSA, 0.05% saponin, and 0.2%
gelatin, the sections were incubated with HRP-conjugated secondary
antibody (P448, goat anti-rabbit immunoglobulin, Dako) for 1 h at
room temperature. After rinsing with PBS wash buffer, the sites of
Fig. 4. Effect of BUO on IM regulation of AQP2 in COX-2/ and wild-type
mice. A: IM AQP2 mRNA level is significantly decreased in response to BUO
in both genotypes. B: total IM AQP2 protein abundance showed significant
downregulation in response to BUO in both genotypes. *P  0.05 BUO-
operated compared with sham-operated mice. ¤P  0.05 BUO-operated
wild-type compared with BUO-operated COX-2/ mice.
Fig. 5. Effect of BUO on COM regulation of AQP3 in COX-2/ and
wild-type mice. A: COM AQP3 mRNA level is significantly decreased in
response to BUO in both genotypes. The downregulation of COM AQP3 is
attenuated in COX-2/ mice. B: COM AQP3 protein abundance is signif-
icantly decreased in BUO wild-type mice. The downregulation of COM
AQP3 is abolished in BUO COX-2/ mice. *P  0.05 BUO compared with
sham-operated mice. #P  0.05 sham-operated wild-type compared with
sham-operated COX-2/ mice. ¤P  0.05 BUO-operated wild-type com-
pared with BUO-operated COX-2/ mice. C–F: cortical immunohistochem-
ical staining of AQP3 showed increased labeling in both COX-2/ sham-
operated and BUO mice compared with wild-type mice. Panels are as de-
scribed in Fig. 3.
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antibody-antigen reactions were visualized with 0.05% 3,3=-diamino-
benzidine tetrachloride (Kem-en Tek, Copenhagen, Denmark) dis-
solved in distilled water with 0.1% H2O2. The light microscope was
carried out with Lecia DMRE (Leica Microsystems).
Statistics
Values are means  SE. Statistical comparison of two experimen-
tal groups was performed by an unpaired Student’s t-test. When
several groups were compared, this was done by two-way ANOVA
followed by post hoc analysis with a t-test and Bonferroni correction.
P values  0.05 were considered significant.
RESULTS
Effect of BUO on Kidney Weight, Plasma Electrolytes,
Creatinine, and Osmolality in Wild-Type and COX-2/
Mice
There was no significant difference between wild-type and
COX-2/ sham-operated mice with regard to body weight or
plasma concentration of sodium and potassium (Table 1). At
baseline, the kidney/body weight ratio was lower, and plasma
urea, creatinine, and osmolality were elevated significantly in
sham-operated COX-2/ compared with wild-type mice (Ta-
ble 1). After introduction of BUO in both wild-type and
COX-2/ mice, kidney weight, plasma osmolality, potas-
sium, creatinine, and urea increased significantly compared
with sham-operated control mice (Table 1). Apart from in-
creased plasma potassium in COX-2/ mice, there was no
significant difference in the parameters between genotypes
after BUO.
Changed COX-2 and COX-1 Expression in Wild-Type Mice
in Response to BUO
The abundance of COX-2 mRNA and protein was signifi-
cantly increased in COM tissue homogenates in wild-type
mice in response to BUO (Fig. 1, A and B). In IM homoge-
nates, the COX-2 protein level was increased in BUO wild-
type mice (Fig. 1C). In COX-2/ mice, there was no detect-
able COX-2 mRNA or protein level (Fig. 1, A–C). Experiments
with IM homogenates revealed that the anti-COX-2 antibody
(Cayman 160126) labeled a protein of the expected molecular
size (	72 kDa). This was completely ablated when the anti-
body was preincubated with an excess of the immunizing
peptide (Fig. 1D). To further support the specificity, additional
analyses were conducted with different antibodies directed
against COX-2 (Cayman 160106 and Abcam ab15191). Both
antibodies confirmed the COX-2 result in response to BUO and
further corroborate the findings (Fig. 1D). Immunohistochem-
ical staining of kidney IM sections revealed that COX-2-
immunoreactive protein was localized to the medullary inter-
stitial cells in the obstructed kidney, and there was no detect-
able labeling in the COX-2/ mice subjected to BUO (Fig. 1,
E and F). At baseline, mice deficient in COX-2 showed a
significant increase in COX-1 protein abundance in both
COM and IM (Fig. 2, A and B). In wild-type mice, COX-1
protein abundance increased after BUO in both COM and IM
compared with sham-operated animals (Fig. 2, A and B); in
COM of COX-2/ mice, COX-1 expression increased fur-
ther in response to BUO whereas it was unaltered at a high
level in the IM (Fig. 2, A and B).
Effect of BUO on Renal AQP2 Abundance and Localization
in Wild-Type and COX-2/ Mice
In COM fraction, total AQP2 mRNA and protein abun-
dance significantly decreased in wild-type BUO-operated mice
compared with sham-operated wild-type mice. In BUO-oper-
ated COX-2/ mice, downregulation of total AQP2 was
attenuated at both mRNA and protein levels (Fig. 3, A and B).
Immunohistochemistry of cortical sections demonstrated that
wild-type mice subjected to BUO showed weaker labeling of
AQP2 in the apical plasma membranes in collecting duct
principal cells compared with sham-operated wild-type mice.
COX-2/ mice subjected to BUO showed stronger labeling of
AQP2 compared with obstructed wild-type mice (Fig. 3, C–F).
AQP2 mRNA levels in the IM did not differ between
sham-operated wild-type and COX-2/ while it was sup-
pressed below 5% of sham levels following obstruction in both
genotypes (Fig. 4A). Total AQP2 protein abundances in the IM
did not differ between genotypes in sham-operated mice. After
BUO induction, AQP2 protein abundances decreased equally
in wild-type and COX-2/ mice compared with sham-oper-
ated mice (Fig. 4B). However, total AQP2 protein was signif-
Fig. 6. Effect of BUO on IM regulation of AQP3 in COX-2/ and wild-type
mice. A: IM AQP3 mRNA level is significantly decreased in response to BUO
in both genotypes. B: IM AQP3 protein abundance is significantly decreased in
wild-type mice in response to BUO. Furthermore, significant upregulation at
baseline is shown in COX-2/ compared with wild-type mice. *P  0.05
BUO-operated compared with sham-operated mice. #P  0.05 sham-operated
wild-type compared with sham-operated COX-2/ mice.
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icantly decreased in COX-2/ compared with wild-type mice
after BUO.
The pAQP2 protein level in COM did not differ between
genotypes as well as sham-operated control and BUO-operated
mice. In the IM, pAQP2 was significantly suppressed in both
genotypes after BUO compared with wild-type mice (data not
shown).
Effect of BUO on Renal AQP3 Abundance and Localization
in Wild-Type and COX-2/ Mice
AQP3 mRNA levels did not differ between genotypes in
COM in sham-operated mice (Fig. 5A). However, at the
protein level AQP3 was increased in the COX-2/ mice (Fig.
5B). Upon obstruction, AQP3 mRNA and protein levels in
COM decreased significantly in wild-type mice, while dele-
tion of COX-2 rescued the AQP3 protein level and improved
the AQP3 mRNA level (Fig. 5, A and B). Immunohistochem-
ical labeling of kidney sections for AQP3 demonstrated that
sham-operated wild-type mice displayed a less marked labeling
pattern associated with cortical collecting duct basolateral
membranes compared with COX-2/ mice (Fig. 5, C vs. D).
After obstruction, wild-type mice exhibited labeling close to
the detection threshold, while labeling of COX-2/ kidneys
subjected to BUO was indistinguishable from sham-operated
COX-2/ mice (Fig. 5, E and F).
In the IM, AQP3 mRNA was not different between COX-
2/ and wild-type mice, while at the protein level AQP3 was
significantly increased in the sham-operated COX-2/ mice
compared with wild-type. AQP3 mRNA level decreased sig-
nificantly after BUO in COX-2/ and wild-type compared
with sham-operated mice, while at the protein level AQP3 was
only significantly reduced in the wild-type BUO-operated mice
(Fig. 6, A and B).
Effect of BUO on Renal AQP Abundance in Parecoxib-Treated
and Control Mice
A last series of experiments tested the effect of a COX-2
inhibitor in sham-operated and BUO wild-type mice. Wild-
type mice were treated with a COX-2 inhibitor and then
subjected to sham operation or BUO, and changes in COX-1,
AQP2, and -3 protein abundances were analyzed.
To examine the effect of the COX-2 inhibitor parecoxib, the
cortical COX-2 mRNA level was measured in treated and
untreated control mice, which demonstrated threefold increase
Fig. 7. Effect of 24-h BUO on COM and IM AQPs in
vehicle- and parecoxib-treated wild-type mice. A: COX-1
protein level in COM. B: AQP2 protein level in COM.
C: AQP3 protein level in COM. D: COX-1 protein level
in IM. E: AQP2 protein level in IM. F: AQP3 protein level
in IM. *P  0.05 BUO-operated compared with sham-
operated mice. #P  0.05 sham-operated, vehicle-treated
compared with sham-operated, parecoxib-treated mice.
¤P  0.05 BUO-operated, vehicle-treated compared with
BUO-operated, parecoxib-treated mice.
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in COX-2 expression in response to parecoxib treatment com-
pared with control mice (COX-2/
-actin ratio: 1.03  0.31 vs.
0.31  0.03, P  0.05) (10, 16). The COX-1 protein level was
increased in BUO-operated mice compared with sham-oper-
ated mice in both COM and IM (Fig. 7, A and D), although
it did not reach a significant level in the IM (P  0.057).
Parecoxib treatment significantly increased COX-1 protein in
COM in sham-operated mice. AQP2 protein abundance was
not significantly regulated in COM in sham-operated control
mice, but there was a tendency of upregulation in response to
parecoxib (Fig. 7B). In BUO-operated mice, there was a
tendency toward a downregulation of AQP2 compared with
sham-operated mice, although it was not significant. In the IM,
AQP2 protein abundance was decreased in response to BUO,
and this downregulation was attenuated by administration of
parecoxib (Fig. 7E). In response to BUO, there was a signifi-
cant downregulation of pAQP2 in the IM. Treatment with
parecoxib increased pAQP2 in COM in sham-operated mice
(data not shown). AQP3 protein abundance was significantly
decreased in BUO-operated compared with sham-operated
mice in COM (Fig. 7C), and a tendency of downregulation in
the IM (Fig. 7F). Administration of the selective COX-2
inhibitor parecoxib partly attenuated the decreased AQP3 pro-
tein level in COM after BUO.
Immunohistochemical staining of cortical sections displayed
a weaker apical AQP2 labeling in collecting duct principal
cells in BUO-operated mice compared with sham-operated
mice (Fig. 8, A vs. C). Cortical labeling of AQP3 showed that
vehicle-treated mice subjected to BUO display weaker labeling
in the basolateral plasma membranes in collecting duct princi-
pal cells compared with sham-operated, vehicle-treated mice
(Fig. 8, E vs. G). Parecoxib-treated, BUO-operated mice ex-
hibited stronger labeling of AQP3 compared with obstructed
vehicle-treated mice, indistinguishable from sham-operated,
parecoxib-treated mice (Fig. 8, E–H).
DISCUSSION
The present study shows that BUO in wild-type mice leads
to a significant induction of COX-1 and COX-2 protein and
downregulation of AQP2 and -3. COX-2 displayed the largest
increase after BUO and was associated with renomedullary
interstitial cells. C57BL/6 mice with disrupted COX-2 (COX-
2/) were protected from BUO-induced suppression of AQP2
and -3 in COM tissue despite compensatory stimulation of
COX-1 protein at baseline. This protection of AQP decreased
protein levels by disruption of COX-2 was partially recapitu-
lated by administration of a specific COX-2 blocker to wild-
type BUO-operated mice. Thus C57BL/6 mice appear as a
valid model that reproduces acute downregulation of AQPs
after BUO in rats, and the data might indicate that downregu-
lation of AQP2 and AQP3 after release of BUO and subsequent
acute polyuria is mediated mainly by COX-2-derived prosta-
glandins.
A minor difference in rescue of AQPs in the IM between
COX-2/ (absent protection) and parecoxib-treated wild-type
(partial protection) mice was detected. This difference is likely
caused by upregulated COX-1 in COX-2/ mice and attenu-
ated COX-1 activity (lower abundance compared with COX-
2/ and partial nonselective inhibition) in wild-type mice
treated with parecoxib.
Changed COX-2 and COX-1 Protein Level in COX-2/ and
Wild-Type Mice in Response to BUO
BUO increases cortical and medullary COX-2 compared
with sham-operated mice, and this increase is abolished in
COX-2/ mice. Consistent with previous rat studies, the
present study shows that COX-2 is increased in renal medul-
lary interstitial cells in response to BUO (16, 18).
As observed recently (19), the present data confirmed that
mice deficient in COX-2 display a compensatory upregulation
of COX-1 and further showed that COX-1 was stimulated by
BUO in the cortex. Thus the mice exhibit a larger sensitivity to
BUO with more widespread upregulation of COX in kidney
tissue compared with rats, for example, where cortical COX-1
Fig. 8. Cortical immunohistochemical staining of AQPs in vehicle- and
parecoxib-treated wild-type mice. A–D: cortical immunohistochemical stain-
ing of AQP2 showed weaker labeling in BUO-operated, vehicle-treated mice
compared with sham-operated mice. A: sham-operated, vehicle-treated.
B: sham-operated, parecoxib-treated. C: BUO-operated, vehicle-treated. D: BUO-
operated, parecoxib-treated. E–H: cortical immunohistochemical staining of
AQP3 showed stronger labeling in parecoxib-treated, BUO-operated mice
compared with vehicle-treated, BUO-operated mice. Panels E–F are as de-
scribed for A–D.
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and -2 did not change after BUO (16). This differential regu-
lation of COX-2 expression between mice and rats has been
observed in previous studies with a low-salt diet, treatment
with a loop diuretic, and an angiotensin-converting enzyme
inhibitor in the cortex (27).
Effect of BUO on Plasma Creatinine and Urea in Wild-Type
and COX-2/ Mice
The observation that sham-operated COX-2/ mice had
increased plasma creatinine and urea is consistent with previ-
ous studies in COX-2/ mice, suggesting reduced renal func-
tion in the COX-2/ mouse (19, 20, 29). Wild-type mice with
BUO exhibited a significant increase in the plasma concentra-
tion of creatinine, urea, potassium, and osmolality compared
with sham-operated mice, consistent with impaired renal func-
tion and previous findings in rats (13, 16). COX-2/ mice
subjected to BUO showed a significant, further, increase in
plasma potassium compared with obstructed wild-type mice.
These results suggest that obstructed mice with homogenous
deletion of COX-2 experience further reduction in renal func-
tion compared with wild-type mice subjected to BUO. COX-
2/ mice have impaired postnatal kidney development. The
defect involves cortical dysplasia, diffuse tubular dilation,
hypoplastic subcapsular glomeruli, and juxtamedullary
nephron hypertrophy (3, 19, 20, 22). In the present study,
COX-2/ mice displayed accumulation of small glomeruli in
the subcapsular region, while the tissue displayed no cysts,
inflammation, or fibrosis. The cortical dysplasia with fewer
functional outer cortical nephrons may account for the ob-
served changes in plasma creatinine and urea. Despite this
injury, the mice were considered suitable to test the hypothesis
because it relates to a pathophysiological situation where the
glomerular filtration rate is reduced experimentally to a mini-
mal level, and because the COX-2/ mouse exhibits AQP
levels that are normal to elevated in the control situation (19).
Moreover, the mouse reacts to BUO similarly to the rat with a
massive COX-2 induction in the medulla.
Effect of BUO on Renal AQP2 and AQP3 in COX-2/ and
Parecoxib-Treated Wild-Type Mice
The present study documented downregulation of renal
AQPs in response to BUO in mice, consistent with several
previous rat studies (11, 16). The downregulation of cortical
AQP2 and AQP3 in response to BUO was attenuated in
COX-2/ mice, whereas no rescue of AQP2 and AQP3 levels
was observed in the IM. Why did COX-2 inhibitor experiments
show protection of AQP2 abundance after BUO in the IM,
similar to in rats (16), while BUO-induced suppression of
AQP2 in the IM of COX-2/ mice was not attenuated? A
likely explanation is the compensatory upregulation of COX-1
by BUO that may supply downstream PGE synthase with
substrate even in the absence of functional COX-2. At baseline,
there are 25 times higher COX-1 levels in the rat IM compared
with the cortex (9). A similar gradient in the mouse with
further COX-1 upregulation by BUO in COX-2/ mice could
account for maintained or even increased prostaglandin syn-
thesis. Parecoxib at 5 mg/kg is likely also to have some
nonselective inhibitory action on COX-1 (24, 26), which may
account for the modest, but significant, attenuation of AQP2
downregulation in the IM after BUO The results further sup-
port that in the setting of BUO, COX-2-derived prostanoids
either directly or by indirect pressure-related effects suppress
transcellular water uptake pathways in the collecting duct.
Recent observations show that PGE2 through EP2/EP4 recep-
tors in rare situations (loss-of-function mutations in the vaso-
pressin receptor) may actually preserve collecting duct AQPs
and support urine concentrating ability (14). In BUO, there is
significant stimulation of prostaglandin synthesis in the renal
medulla, while in nephrogenic diabetes insipidus, medullary
prostaglandin synthesis is maximally suppressed (8, 18, 28).
These very different physiological settings probably account
for the different roles associated with prostaglandins to control
AQPs.
In summary, the present data show that 1) the mouse
essentially recapitulates the observations from the rat that
ureteral obstruction induces renal COX-2 expression and low-
ers aquaporin abundance and 2) inhibition of COX-2 activity
by targeted disruption or pharmacological blockade in the
mouse attenuates obstruction-induced AQP downregulation.
The data further support that COX-2-derived prostaglandins
contribute to postobstruction diureses and mice with targeted
disruption of key signaling molecules could be employed to
dissect the cellular events that injure kidney structure and
function after ureteral obstruction.
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